ImetelChat

Hi Irish, thanks for your highly informative posts! I am not aware of any existing and publicly available comparative data. But JnJ should have some idea by now, so does Dr.T. For patients this is very important information. It could mean a high risk patient may be better to take interferon (e.g. th...

Rob, I am not sure. Geron goes well as from second half 2014. Consistant positive news, or news that confirm that imetelstat is going according to plan. Maybe people are losing their patience. Or shorts are using this news to play their games. They need to cover at these low levels. The call was in ...

MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been comple...

Some comments from SA: Leviek: "Scarlet has repeatedly stated that no announcements would be made regarding the interim results, which are highly likely to be known at this time. It is September, and they have repeatedly said the interim results will be known by the end of the third quarter, about 1...

MENLO PARK, Calif., Sept. 11, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016, at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndromes. Participants can...

Dominic Caruso, SVP and CFO of J&J from today's Wells Fargo healthcare conference: "So we’re, obviously, very pleased with the pharmaceutical business and we think that the growth of that business – and I'm not going to quote a particular percentage growth, but the overall robust growth that we see ...

And they are leaving out anything that is commercially sensitive.

Hi Irish, great to see your here again with the good news about John!

I believe it was posted on SA

That's right. I just mean to say that the angle is different. When patients are being informed, doctors tend to be very cautious with new data and drugs that are under development. Tefferi always has been cautious, so have been others (like Mesa, Verstovsek etc.). So I am not anticipating new front ...

Cheng, this meeting is about informing patients, not investors.

Hunt, thanks for this important info. Many people will be gratefull for that. Now let's see how this works in the EU...

Tangken, thanks for clearing this up.

At least I give credits for Sdrawkcabeman for having put this waiver into the perspective of the complex EMA approval process. I agree with him that it is ticking a box on the way to market authorization, although it is just a formality.

Not so synical, Cheng. Teffri IS speaking on the 16th: This is the 2nd Annual SF Bay Area MPN Conference for Patients. You will have the opportunity to hear the latest research and engage with four experts in the MPN clinical and scientific community. Confirmed to attend are Dr. Ayalew Tefferi from ...

By Sdrawkcabeman, YMB, 28 August 2016 Some further deliberation on Anne’s post about the waiver, http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500212174.pdf Firstly, the decision refers to: “Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Cou...

According to my personal notes Dr.Scarlett mentioned the AML for 2H 2016 on the Needham Healthcare Conference of 12 April this year. Does anyone have a transcript or audio file?

Hi Hunt, thanks for telling your experiences. I think you are right about going through your own physician first. For a doctor like Tefferi it is an important reference and also a gate to prevent every single individual to contact him directly. I am not sure from you story if the own doctor of your ...

So we are (or at least I am) assuming that the AML trial was scheduled for 2H 2016 and that its still on track. That is because I saw/heard it with one of the calls/presentations. I also remember Dr. Scarlett confirming that the planning of the AML trial for 2H 2016 was still on track. My problem is...

(by Hoosier, Seeking Alpha 24 August 2016) "In my opinion, Geron management is very serious about their effort to identify potential acquisition candidates. I say this because their long-term corporate strategy is a function of their ability to identify suitable acquisition candidates. Based on the ...